Rescuing the last-line polymyxins: achievements and challenges
Antibiotic resistance is a major global health challenge and, worryingly, several key Gram
negative pathogens can become resistant to most currently available antibiotics. Polymyxins …
negative pathogens can become resistant to most currently available antibiotics. Polymyxins …
Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections
In recent years, the worldwide spread of the so-called high-risk clones of multidrug-resistant
or extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa has become a public …
or extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa has become a public …
RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with …
J Motsch, C Murta de Oliveira, V Stus… - Clinical Infectious …, 2020 - academic.oup.com
Background The β-lactamase inhibitor relebactam can restore imipenem activity against
imipenem-nonsusceptible gram-negative pathogens. We evaluated imipenem/relebactam …
imipenem-nonsusceptible gram-negative pathogens. We evaluated imipenem/relebactam …
[HTML][HTML] Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli
L Scudeller, E Righi, M Chiamenti, D Bragantini… - International journal of …, 2021 - Elsevier
Background: The superiority of combination therapy for carbapenem-resistant Gram-
negative bacilli (CR-GNB) remains controversial. In vitro models may predict the efficacy of …
negative bacilli (CR-GNB) remains controversial. In vitro models may predict the efficacy of …
Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans
JB Bulitta, WW Hope, AE Eakin, T Guina… - Antimicrobial agents …, 2019 - Am Soc Microbiol
ABSTRACT In June 2017, the National Institute of Allergy and Infectious Diseases, part of
the National Institutes of Health, organized a workshop entitled “Pharmacokinetics …
the National Institutes of Health, organized a workshop entitled “Pharmacokinetics …
[HTML][HTML] Colistin: new lessons on an old antibiotic
D Yahav, L Farbman, L Leibovici, M Paul - Clinical microbiology and …, 2012 - Elsevier
Colistin has been re-introduced into clinical practice for the treatment of carbapenem-
resistant Gram-negative bacteria. Studies in the last decade attempted to reconstruct the …
resistant Gram-negative bacteria. Studies in the last decade attempted to reconstruct the …
Systematic Review and Meta-Analysis of In Vitro Synergy of Polymyxins and Carbapenems
Our objective was to examine the evidence of in vitro synergy of polymyxin-carbapenem
combination therapy against Gram-negative bacteria (GNB). A systematic review and meta …
combination therapy against Gram-negative bacteria (GNB). A systematic review and meta …
Updated US and European dose recommendations for intravenous colistin: how do they perform?
Abstract Background. The US Food and Drug Administration (FDA) and European
Medicines Agency (EMA) have approved updated dose recommendations for intravenous …
Medicines Agency (EMA) have approved updated dose recommendations for intravenous …
Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria
T Tängdén - Upsala journal of medical sciences, 2014 - Taylor & Francis
Combination antibiotic therapy for Gram-negative sepsis is controversial. The present review
provides a brief summary of the existing knowledge on combination therapy for severe …
provides a brief summary of the existing knowledge on combination therapy for severe …
Pharmacokinetics and pharmacodynamics of 'old'polymyxins: what is new?
'Old'colistin and polymyxin B are increasingly used as last-line therapy against multidrug-
resistant Gram-negative bacteria Pseudomonas aeruginosa, Acinetobacter baumannii, and …
resistant Gram-negative bacteria Pseudomonas aeruginosa, Acinetobacter baumannii, and …